Cyclerion Therapeutics

Cyclerion Therapeutics, Inc. is a biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for central nervous system and peripheral diseases, including CYC-126 for treatment-resistant depression and olinciguat for cardiovascular indications. On April 1, 2026 the company announced a definitive all-stock merger agreement with privately-held Korsana Biosciences; the combined company is expected to operate as Korsana Biosciences, trade on Nasdaq under KRSA, and advance KRSA-028, a next-generation shuttled monoclonal antibody targeting amyloid beta for Alzheimer's disease, supported by a concurrent private financing of approximately $380 million. Cyclerion set the close of business on September 4, 2026 as the record date for a contingent-value-right (CVR) distribution to holders in connection with the merger, and the business combination is expected to close September 8, 2026 — with Cyclerion common stock undergoing a 1-for-7 reverse split and a change of name, symbol, and CUSIP.